Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OriV508 in Relapsed/Refractory Hematological Malignancies
NCT07101705Phase 1Recruiting
- Start
- Sep 2025
- Primary completion
- Aug 2028
- Modality
- CAR-T Cells, Lentiviral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OriV508 in multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). Primary endpoints: Dose-limiting toxicities at 28 days, Cytokine release syndrome at 28 days and 2 more. Started Sep 2025; status: recruiting.
02
Drugs
OriV508
03
Conditions
multiple myeloma (MM)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07101705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07101705.